Probiotix Health PLC Appointment of Non-Executive Director

RNS Number : 0564H

Probiotix Health PLC

07 October 2024

 

7 October 2024

                                                                                                                                 

ProBiotix Health plc

("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")

 

Appointment of Non-Executive Director

 

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce that, further to the announcement of 4 September 2024, Frederik Bruhn-Petersen has been appointed as a Non-executive Director of the Company.

 

Frederik is currently working in a managing role for Holdingselskabet af 29. Juni 2010 Aps, an investment vehicle of the Bruhn-Petersen family, which is interested in 33,160,000 ordinary shares in the Company, representing 20.97% of the Company's current issued share capital.

 

Frederik is an entrepreneur and is the co-founder of RobinHus A/S, a disruptive real estate brokerage in Denmark, driving the business from its start-up phase to a national franchise based operator, before ultimately selling to Denmark's largest real estate player, EDC A/S. Frederik has a Masters of Law Degree from Copenhagen University.

 

Frederik is interested in 3,000,000 ordinary shares in the Company.

 

For further information, please contact:

 

ProBiotix Health plc		https://probiotixhealth-ir.com/
Steen Andersen, Chief Executive Officer		Contact via Walbrook below
Peterhouse Capital Limited (Aquis Corporate Adviser and Broker)			Tel: [phone]
Mark Anwyl
Walbrook PR Ltd	[e-mail] or 07876 741 001
Anna Dunphy

 

Save as set out below, there is no further information regarding Frederik Bruhn-Petersen that is required to be disclosed pursuant to Rule 4.9 of the Aquis Growth Market Access Rulebook.

 

CURRENT DIRECTORSHIPS

VICS 6998 ApS

HCS 82 ApS

K/S BAXTERGATE (DONCASTER)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NEXMZMGGKDFGDZM